About DexCom, Inc. 
DexCom, Inc.
Pharmaceuticals & Biotechnology
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).
Company Coordinates 
Company Details
6340 Sequence Dr , SAN DIEGO CA : 92121-4356
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 186 Schemes (47.57%)
Foreign Institutions
Held by 485 Foreign Institutions (26.91%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. Kevin Sayer
Chairman of the Board, President, Chief Executive Officer
Mr. Mark Foletta
Lead Independent Director
Mr. Steven Altman
Independent Director
Mr. Nicholas Augustinos
Independent Director
Mr. Richard Collins
Independent Director
Ms. Karen Dahut
Independent Director
Revenue and Profits:
Net Sales:
1,157 Million
(Quarterly Results - Jun 2025)
Net Profit:
180 Million
Pharmaceuticals & Biotechnology
USD 30,658 Million (Mid Cap)
64.00
NA
0.00%
-0.18
22.21%
11.91






